Skip to main content

Value Stock - Dividend - Research Selection


Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Key figures
Cash flow
Balance sheet
Income statement
Div. Yield%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization USD
Raw Data Source
Stock Split

Description of the company

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


Tracking Kahn Brothers Portfolio - Q3 2022 Update

Kahn Brothers’ 13F portfolio value decreased from ~$743M to ~$642M this quarter. Click here to read more about the holdings and trades for Q3 2022.

Organon & Co. (OGN) Presents at Piper Sandler 34th Annual Healthcare Conference

Organon & Co. (NYSE:NYSE:OGN) Piper Sandler 34th Annual Healthcare Conference November 29, 2022 09:00 AM ET Company Participants Kevin Ali - Chief Executive Officer Matt Walsh - Chief...

Organon: Q3 Results Show Promising Acquisitions But Mixed Portfolio Sales

Organon's Q3 results show third consecutive quarter of growth. Read more to see OGN's recent acquisitions and why I'm adding it to my watchlist.

Organon To Present at the Piper Sandler 34th Annual Healthcare Conference

JERSEY CITY, N.J., November 15, 2022--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29th, 2022 at 9:00 a.m. EST.

Godshalk Welsh Capital Managem -

GuruFocus Article or News written by insider and the topic is about:

UK shareholder meetings calendar - next 7 days

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

Organon Announces Formal Commitment to FP2030 To Help Prevent 120 Million Unintended Pregnancies in Low- and Middle-Income Countries Around the World

Organon (NYSE:OGN), a global women's healthcare company, today announced its formal commitment to FP2030 to help prevent 120 million unintended pregnancies by 2030. Recognizing the urgency of the crisis, Organon is taking action to scale access to contraceptive options for more than 100 million women in low- and middle-income countries (LMICs), in addition to strategic partnerships focused on education, training, advocacy and youth engagement.

Organon Canada launches Ontruzant®, a biosimilar of the reference biologic Herceptin®, providing patients in Canada with certain breast and gastric cancers with an additional therapeutic option at a lower cost

Organon (NYSE: OGN), a global women's health company, today announced the availability and distribution of Ontruzant®, a biosimilar of Herceptin®, providing an additional treatment option for Canadian adults diagnosed with early breast cancer (EBC), metastatic breast cancer (MBC) and metastatic gastric cancer (MGC).1

SECTOR GAMMA AS Buys 1, Sells -

GuruFocus Article or News written by insider and the topic is about:

Organon Canada launches Aybintio®, a biosimilar of the reference biologic Avastin®, providing a new option at a reduced cost for Canadians living with certain aggressive forms of cancer

Organon (NYSE: OGN), a global women's health company, is announcing the launch and product availability of Aybintio®, a biosimilar of Avastin®, providing a new treatment option for adult Canadian patients affected with certain aggressive forms of cancers, including metastatic colorectal cancer (mCRC), locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC), platinum-sensitive recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer, platinum-resistant recur